Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Publication of Circular

4th Jun 2014 16:46

RNS Number : 8713I
PuriCore Plc
04 June 2014
 



 

PuriCore plc("PuriCore" or the "Company") Publication of Circular 

4 June 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces the publication of its Circular in connection with the proposed disposal of PuriCore International Limited, details of which were announced earlier today.

 

The Circular has been approved by the UK Listing Authority. A copy of the Circular is available from the Company's investor website at investor.puricore.com, and a copy has been submitted to the National Storage Mechanism and will be available shortly for inspection at www.hemscott.com/nsm.do.

 

Enquiries:

 

PuriCore plc

Michael Ashton/Marella Thorell

+1.484.321.2700

Jennifer Guinan

+1 610.410.6111

Peel Hunt LLP (Sponsor, Financial Adviser and Broker)

+44 (0) 20 7418 8900

Daniel Harris/Euan Brown

FTI Consulting

+44 (0) 20 7831 3113

Simon Conway/Mo Noonan/Victoria Foster Mitchell

 

 

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients and staff in UK hospitals. PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. In the Food & Agriculture market, PuriCore's portfolio is used by three of the top-five US supermarket retailers to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In addition, the Company is progressing its research and development programmes on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEZLFBZQFZBBL

Related Shares:

RLM.L
FTSE 100 Latest
Value8,811.04
Change9.75